Skip to main content

Table 1 Clinical characteristics of the study population. ECOG, Eastern Cooperative Oncology Group; SBRT, stereotactic body radiotherapy; GFR, glomerular filtration rate; PTV, planning target volume

From: Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial

Parameter

Value (Percent/Range)

Median (range) age, years

63 (35–80)

Gender

 Male

23 (60.5%)

 Female

15 (39.5%)

ECOG performance status

 0

13 (34.2%)

 1

20 (52.6%)

 2

5 (13.2%)

 3

0 (0%)

History of chronic kidney disease

 Yes

0 (0%)

 No

38 (100%)

Nephroaffective medication at diagnosis

 Metformin

6 (16%)

 ACE inhibitors

3 (8%)

Median (range) tumor size, cm

3.0 (0.8–6.5)

Resectability status

 Borderline resectable

13 (34.2%)

 Unresectable

25 (65.8%)

Median (range) pre-SBRT creatinine, mg/dL

0.8 (0.5–1.4)

Median (range) pre-SBRT GFR, mL/min/1.73 m2

96.8 (50.1–142.0)

Median (range) post-SBRT creatinine peak, mg/dL

1.1 (0.5–3.57)

Median (range) pre-SBRT GFR nadir, mL/min/1.73 m2

61.6 (12.9–147.7)

Median (range) contoured volume of kidneys, cm3

355 (187–726)

Median (range) PTV volume, cm3

130 (59–275)

SBRT technique

 Fixed-beam

36 (94.7%)

 Arc

2 (5.3%)

Receipt of pancreaticoduodenectomy

 Yes

10 (26.3%)

 No

28 (73.7%)